HASBROUCK HEIGHTS, N.J., May 27, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the presenters and participants for the symposium and panel discussion on NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), to be held during the 2010 Annual Meeting of the American Urological Association in San Francisco at 3:00 p.m. June 1.

The symposium, "Progress with NX-1207: Phase 3 Pro-Apoptotic Injectable for BPH," will be chaired by Neal D. Shore, MD, FACS, CPI, of Myrtle Beach, SC, who has participated in five of the prospective NX-1207 clinical trials as well as ten follow-up studies. Dr. Shore will present an overview of NX-1207 and the NX-1207 clinical trials to date, including the two Phase 3 clinical trials currently in progress.

Barrett E. Cowan, MD, FACS, of Denver, CO, will present data from the new studies of the long term efficacy of NX-1207 treatment. Chris B. Threatt, MD of Atherton, CA, Barton H. Wachs, MD, FACS, of Long Beach, CA, Dr. Shore, and Dr. Cowan will participate in the panel discussion in the symposium.

All four symposium panelists are distinguished Board-certified urologists with clinical expertise and extensive knowledge as clinical investigators in FDA-regulated clinical trials, including the NX-1207 clinical trials.

NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 6½ years.

NX-1207 has entered its Phase 3 development program, the last stage before filing with the FDA for approval. NX-1207 is injected by a urologist in an office setting and involves little or no pain or discomfort. For more information about the NX-1207 Phase 3 clinical trials please go to www.clinicaltrials.gov or contact Nymox at info@nymox.com.

BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT:  Nymox Pharmaceutical Corporation          Roy Wolvin          1-800-93NYMOX          www.nymox.com